MEDS

DataMEDS AI, Inc.
CAPPED RATING

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

DataMEDS AI, Inc. (MEDS) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
B-
Factor Score 3.0 / 5.0
Growth
F
Factor Score 0.3 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
D
Factor Score 1.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -0.6
Rev Growth YoY -77.2%
Gross Margin -90.6%
Price Return 3M -41.2%
Price Return 12M -97.1%
Catalyst Signal 0.00
Market Cap $4.5M
TTM Revenue $8.0M
Price / Sales 0.6
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) F (0.3) C- (1.9) D (1.4) C+ (2.6) C- (1.9)
2026-11-06 B- (3.0) F (0.3) D+ (1.8) D (1.5) C+ (2.7) D+ (1.8)
2026-10-30 B- (3.0) F (0.3) D+ (1.8) D (1.4) C+ (2.7) D+ (1.8)
2026-10-23 B- (3.0) F (0.3) D+ (1.8) D (1.4) C+ (2.6) D+ (1.8)
2026-10-16 B- (3.0) F (0.3) D+ (1.8) C (2.4) C+ (2.6) C- (2.0)
Page 1 of 4